Status:
COMPLETED
Transplantation and the Use of Raltegravir in HIV-Infected Patients
Lead Sponsor:
Duke University
Collaborating Sponsors:
Merck Sharp & Dohme LLC
Conditions:
HIV Positive
Organ Transplant Recipient
Eligibility:
All Genders
13-80 years
Brief Summary
Raltegravir (RAL) is a preferred option for initial antiretroviral therapy in the most recent HIV Treatment Guidelines and is emerging as a popular choice for use in the specialized population of HIV-...
Detailed Description
Pre-transplant: * Patients on stable antiretroviral regimens who undergo evaluation for transplantation and are subsequently placed on the transplant waiting list will be considered for inclusion in ...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- non-pregnant adult patient with CD4 count \>200/μL
- no concurrent active AIDS-defining infections or malignancy
- at least 24 months of well controlled HIV viremia, defined as \<50 copies for the majority of the time.
- otherwise suitable transplant candidates, actively listed
- currently taking Raltegravir for control of HIV infection
Exclusion
Key Trial Info
Start Date :
October 1 2012
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 1 2017
Estimated Enrollment :
17 Patients enrolled
Trial Details
Trial ID
NCT01793467
Start Date
October 1 2012
End Date
June 1 2017
Last Update
August 16 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Duke University Medical Center
Durham, North Carolina, United States, 277138270